{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T05:06:26Z","timestamp":1751519186099},"reference-count":39,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2014]]},"DOI":"10.2169\/internalmedicine.53.1488","type":"journal-article","created":{"date-parts":[[2014,5,31]],"date-time":"2014-05-31T23:22:11Z","timestamp":1401578531000},"page":"1209-1213","source":"Crossref","is-referenced-by-count":12,"title":["Steroid-sparing Effects of Etanercept in a Patient with Steroid-dependent Adult-onset Still's Disease"],"prefix":"10.2169","volume":"53","author":[{"given":"Yasuhiro","family":"Kiyonaga","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Maeshima","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiharu","family":"Imada","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miwa","family":"Haranaka","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Franchini S, Dagna L, Salvo F, Aiello P, Baldissera E, Sabbadini MG. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. Arthritis Rheum 62: 2530-2535, 2010.","DOI":"10.1002\/art.27532"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Husni ME, Maier AL, Mease PJ, et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 46: 1171-1176, 2002.","DOI":"10.1002\/art.10231"},{"key":"3","unstructured":"3. Fautrel B, Sibilia J, Mariette X, Combe B, Club Rhumatismes et I. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 64: 262-266, 2005."},{"key":"4","unstructured":"4. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 19: 424-430, 1992."},{"key":"5","unstructured":"5. Kong XD, Xu D, Zhang W, Zhao Y, Zeng X, Zhang F. Clinical features and prognosis in adult-onset Still's disease: a study of 104 cases. Clin Rheumatol 29: 1015-1019, 2010."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Fujii T, Nojima T, Yasuoka H, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology (Oxford) 40: 1398-1404, 2001.","DOI":"10.1093\/rheumatology\/40.12.1398"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130: 478-486, 1999.","DOI":"10.7326\/0003-4819-130-6-199903160-00004"},{"key":"8","unstructured":"8. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340: 253-259, 1999."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Stern A, Riley R, Buckley L. Worsening of macrophage activation syndrome in a patient with adult onset Still's disease after initiation of etanercept therapy. J Clin Rheumatol 7: 252-256, 2001.","DOI":"10.1097\/00124743-200108000-00013"},{"key":"10","unstructured":"10. Asherson RA, Pascoe L. Adult onset Still's disease: response to Enbrel. Ann Rheum Dis 61: 859-860, 2002."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Serratrice J, Granel B, Disdier P, Weiller PJ, Dussol B. Resolution with etanercept of nephrotic syndrome due to renal AA amyloidosis in adult Still's disease. Am J Med 115: 589-590, 2003.","DOI":"10.1016\/j.amjmed.2003.04.001"},{"key":"12","unstructured":"12. La Montagna G, Valentini G. Listeria monocytogenes meningitis in a patient receiving etanercept for Still's disease. Clin Exp Rheumatol 23: 121, 2005."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J. Refractory adult onset Still's disease successfully treated with anakinra. Ann Rheum Dis 64: 647-648, 2005.","DOI":"10.1136\/ard.2004.026617"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 52: 1794-1803, 2005.","DOI":"10.1002\/art.21061"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kumari R, Uppal SS. Prolonged remission in adult-onset Still's disease with etanercept. Clin Rheumatol 25: 106-108, 2006.","DOI":"10.1007\/s10067-004-1064-7"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Thonhofer R, Soleiman A, Kriessmayr M, et al. Decrease of proteinuria in a patient with adult-onset Still's disease and glomerulonephritis after anti-TNFalpha therapy. Scand J Rheumatol 35: 485-488, 2006.","DOI":"10.1080\/03009740600844688"},{"key":"17","unstructured":"17. Kuek A, Weerakoon A, Ahmed K, Ostör AJ. Adult-onset Still's disease and myocarditis: successful treatment with intravenous immunoglobulin and maintenance of remission with etanercept. Rheumatology (Oxford) 46: 1043-1044, 2007."},{"key":"18","unstructured":"18. Kötter I, Wacker A, Koch S, et al. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum 37: 189-197, 2007."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Murakami K, Fujii T, Yukawa N, et al. Successful treatment of a patient with refractory adult Still's disease by tacrolimus. Modern Rheumatol 17: 167-170, 2007.","DOI":"10.1007\/s10165-006-0559-2"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ruiz PJ, Masliah E, Doherty TA, Quach A, Firestein GS. Cardiac death in a patient with adult-onset Still's disease treated with the interleukin 1 receptor inhibitor anakinra. Ann Rheum Dis 66: 422-423, 2007.","DOI":"10.1136\/ard.2006.060541"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Gianella S, Schaer DJ, Schwarz U, et al. Retinal microangiopathy and rapidly fatal cerebral edema in a patient with adult-onset Still's disease and concurrent macrophage activation syndrome. Am J Hematol 83: 424-427, 2008.","DOI":"10.1002\/ajh.21084"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Yang DH, Chang DM, Lai JH, et al. Etanercept as a rescue agent in patient with adult onset Still's disease complicated with congestive heart failure. Rheumatol Int 29: 95-98, 2008.","DOI":"10.1007\/s00296-008-0619-3"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. De Bandt M, Saint-Marcoux B. Tocilizumab for multirefractory adult-onset Still's disease. Ann Rheum Dis 68: 153-154, 2009.","DOI":"10.1136\/ard.2008.088179"},{"key":"24","unstructured":"24. Yoshimura M, Makiyama J, Koga T, et al. Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD). Clin Exp Rheumatol 28: 141-142, 2010."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kaneko K, Kaburaki M, Muraoka S, et al. Exacerbation of adult-onset Still's disease, possibly related to elevation of serum tumor necrosis factor-alpha after etanercept administration. Int J Rheum Dis 13: e67-e69, 2010.","DOI":"10.1111\/j.1756-185X.2010.01544.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Sumida K, Ubara Y, Hoshino J, et al. Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab. Clin Rheumatol 29: 1191-1194, 2010.","DOI":"10.1007\/s10067-010-1418-2"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Perdan-Pirkmajer K, Praprotnik S, Tomsic M. A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature. Clin Rheumatol 29: 1465-1467, 2010.","DOI":"10.1007\/s10067-010-1553-9"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Rech J, Ronneberger M, Englbrecht M, et al. Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade. Ann Rheum Dis 70: 390-392, 2011.","DOI":"10.1136\/ard.2010.129403"},{"key":"29","unstructured":"29. Thonhofer R, Hiller M, Just H, Trummer M, Siegel C, Dejaco C. Treatment of refractory adult-onset Still's disease with tocilizumab: report of two cases and review of the literature. Rheumatol Int 31: 1653-1656, 2011."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Ostrowski RA, Tehrani R, Kadanoff R. Refractory adult-onset still disease successfully treated with abatacept. J Clin Rheumatol 17: 315-317, 2011.","DOI":"10.1097\/RHU.0b013e31822c53ad"},{"key":"31","unstructured":"31. Suematsu R, Ohta A, Matsuura E, et al. Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan. Modern Rheumatol 22: 712-719, 2012."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Maeshima K, Ishii K, Iwakura M, et al. Adult-onset Still's disease with macrophage activation syndrome successfully treated with a combination of methotrexate and etanercept. Modern Rheumatol 22: 137-141, 2012.","DOI":"10.3109\/s10165-011-0477-9"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Kato T, Noguchi K, Uehara M, et al. Angioedema of the periorbital region that developed during treatment with etanercept in a case of refractory adult-onset Still's disease. Intern Med 51: 2801-2804, 2012.","DOI":"10.2169\/internalmedicine.51.8243"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Quismorio A, Brahmbhatt B, Houng M, Panush RS. Etanercept allergy and anaphylaxis. J Rheumatol 39: 2225-2226, 2012.","DOI":"10.3899\/jrheum.120791"},{"key":"35","unstructured":"35. Giampietro C, Ridene M, Lequerre T, et al. Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res 65: 822-826, 2013."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordstrom DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS ONE 7: e30275, 2012.","DOI":"10.1371\/journal.pone.0030275"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 65: 379-384, 2006.","DOI":"10.1136\/ard.2005.035287"},{"key":"38","unstructured":"38. Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 70: 2148-2151, 2011."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 9: 164-172, 2013.","DOI":"10.1038\/nrrheum.2013.4"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/11\/53_53.1488\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:50:51Z","timestamp":1621446651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/11\/53_53.1488\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.53.1488","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}